ReviewOxidative medicine and cellular longevity2021
Therapeutic Value of miRNAs in Coronary Artery Disease.
Review in Oxidative medicine and cellular longevity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Circulating miRNA-21 as early potential diagnostic biomarker for acute myocardial infarction: a meta-analysis.Frontiers in cardiovascular medicine · 2024Pooled it
- Pooled it
- Discovery of miRNAs unique to actively transcribed erythroparvovirus infection in heart failure patients.ESC heart failure · 2025Article
- microRNA-Mediated Regulation of Oxidative Stress in Cardiovascular Diseases.Journal of clinical laboratory analysis · 2025Review
- Knowledge, attitude and practice of pediatric healthcare staff towards the therapy for patients with congenital heart disease.BMC medical education · 2024Article
- Impact of microRNAs on cardiovascular diseases and aging.The Journal of international medical research · 2024Review
- Clinical Significance of MicroRNAs, Long Non-Coding RNAs, and CircRNAs in Cardiovascular Diseases.Cells · 2023Review
- Mechanism of salidroside against coronary artery disease by network pharmacology analysis.BMC complementary medicine and therapies · 2023Article
- MicroRNAs as Biomarkers for Coronary Artery Disease Related to Type 2 Diabetes Mellitus-From Pathogenesis to Potential Clinical Application.International journal of molecular sciences · 2022Review
- Upregulated circulating mir-424 and its' diagnostic value for gram-negative bacteremia after thoracic transplantation.Non-coding RNA research · 2022Article
- Clinical Application of Serum microRNAs in Atherosclerotic Coronary Artery Disease.Journal of clinical medicine · 2022Review
- Integrative analyses of immune-related biomarkers and associated mechanisms in coronary heart disease.BMC medical genomics · 2022Article
- miR-146b-5p activation of hepatic stellate cells contributes to the progression of fibrosis by directly targeting HIPK1.Experimental and therapeutic medicine · 2022Article
- m6A regulator-mediated RNA methylation modification patterns are involved in immune microenvironment regulation of coronary heart disease.Frontiers in cardiovascular medicine · 2022Article
- Expression of miR-1-3p, miR-16-5p and miR-122-5p as Possible Risk Factors of Secondary Cardiovascular Events.Biomedicines · 2021Article
- Biomarkers to monitor the prognosis, disease severity, and treatment efficacy in coronary artery disease.Expert review of cardiovascular therapyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerotic ischemic coronary artery disease (CAD) is a significant community health challenge and the principal cause of morbidity and mortality in both developed and developing countries for all ethnic groups. The progressive chronic coronary atherosclerosis is the main underlying cause of CAD. Although enormous progress occurred in the last three decades in the management of cardiovascular diseases, the prevalence of CAD continues to increase worldwide, indicating the need for discovery of deeper molecular insights of CAD mechanisms, biomarkers, and innovative therapeutic targets. Recently, several research groups established that microRNAs essentially regulate various cardiovascular development and functions, and a deregulated cardiac enriched microRNA profile plays a vital role in the pathogenesis of CAD and its biological aging. Numerous studies established that over- or downregulation of a single miRNA gene by ago-miRNA or anti-miRNA is enough to modify the CAD disease process, significantly prevent age-dependent cardiac cell death, and markedly improve cardiac function. In the light of more recent experimental and clinical evidences, we briefly reviewed and discussed the involvement of miRNAs in CAD and their possible diagnostic/therapeutic values. Moreover, we also focused on the role of miRNAs in the initiation and progression of the atherosclerosis plaque as the strongest risk factor for CAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.